The Expanding Clinical Relevance of FLT3 Mutations in the Treatment of Patients with R/R AML
Experts say that nearly all patients with acute myeloid leukemia (AML) express at least one genetic mutation. But what is the clinical significance of these mutations? In this brief video, Drs Naval Daver and Naveen Pemmaraju, associate professors of leukemia at MD Anderson Cancer Center, explain that these mutations are not simply bystanders in some cases; some have clinically valuable prognostic and therapeutic implications.
Drs Daver and Pemmaraju have entered into written agreements with Astellas for payment for their services in connection with this program.
